Medications

This label is the official prescribing information for intravenous/intramuscular methylprednisolone (SOLU‑MEDROL). Corticosteroids are commonly used short‑term in IBD to treat moderate-to-severe flares when rapid...

VEOIBD often has a strong genetic component and different clinical needs than adult IBD; this study shows genetic findings and treatment challenges in a Middle East pediatric center, which may affect diagnosis and access...

Intestinal fibrosis (stricture) is a serious, hard-to-treat complication of IBD/Crohn's disease. This preclinical study tests whether an antifibrotic drug used in lung fibrosis might reduce fibrosis in the gut, which...

For patients hospitalized with steroid-refractory ASUC, an effective oral rescue option could be useful when standard biologics are unavailable or contraindicated. The study also highlights that high colonic CMV DNA may...

B cells and antibodies appear to play active, regulatory roles in gut inflammation and tissue organization in IBD. Understanding this axis could inform new therapies or biomarkers that change how inflammation is detected...

This paper describes a new engineered, off-the-shelf regulatory T cell therapy (TRX103) designed to restore immune tolerance and that is already entering early clinical trials for treatment-refractory Crohn’s disease.

Infliximab dosing can be hard to personalize. This study shows that selecting pharmacokinetic models based on IBD type and severity can improve how well drug levels are predicted, which could help tailor dosing for...

Identifying genetic predictors of thiopurine-induced leukopenia could help prevent a serious drug side effect by improving pre-treatment genetic screening and dose decisions for people with IBD.

Perianal fistulas are a serious complication of Crohn’s disease with limited high-quality trial evidence. This randomized trial suggests ustekinumab may increase the chance of combined clinical and MRI remission at 12...

This trial is testing whether a rectally delivered probiotic can change the gut microbiome and promote mucosal healing in people with mild-to-moderate ulcerative colitis (and includes some Crohn's patients). If...

This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.

This FDA label update affects people with IBD because tofacitinib is an approved JAK inhibitor for moderately to severely active ulcerative colitis and carries serious safety warnings that may influence treatment choices...

This study looks at how statistically "fragile" results are in trials of new IBD treatments. Patients and clinicians should know that trial size, treatment type, and whether the result was a primary outcome affect how...

This label update affects people with Crohn’s disease or ulcerative colitis because it spells out approved uses, age ranges, and the official dosing schedules and safety warnings for ustekinumab (STELARA). Changes in the...

Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Medications. The original article is from hmpgloballearningnetwork.com.

m6A RNA methylation regulators are emerging as potential targets that may influence immune-driven inflammation in diseases that matter to people with IBD. Understanding these pathways could point toward new precision...

Reactive TDM can help determine why a child with Crohn's disease is losing response to adalimumab and guide whether to escalate dose or switch biologics, which affects short-term management decisions.

This real-world, multicenter study suggests risankizumab can induce clinical and steroid-free remission and mucosal healing in many patients with Crohn disease who previously failed advanced therapies, which may be...

New oral drugs that act mainly in the gut could offer more convenient options and potentially fewer systemic side effects for people with UC or Crohn’s disease. Early clinical signals and a planned Phase 2 trial mean...

This trial explores whether oral ozanimod can induce and maintain remission in children and adolescents with moderate to severe ulcerative colitis who have not responded to standard therapies. Pediatric-specific evidence...

If validated, an early drop in fecal calprotectin could help identify patients on biologic therapy who are likely to achieve mucosal healing without waiting for invasive endoscopy, allowing earlier decisions about...

Perianal fistulizing Crohn's disease is a disabling complication; a subcutaneous form of infliximab could lower treatment burden and expand options if its effectiveness and safety in this specific setting are confirmed.

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from msn.com.

A rare but serious colitis linked to ocrelizumab is described and managed successfully with ciclosporin in a steroid‑refractory case; this may be relevant to clinicians caring for patients on B‑cell–depleting therapy.

This study identifies NR1D1 activation by the experimental drug SR9009 as a potential way to reduce inflammation and improve colon pathology in a mouse model of obesity-associated ulcerative colitis.

Guidelines recommend treating objective inflammation even when symptoms are mild because untreated disease can cause complications; the article describes escalation to risankizumab due to endoscopic inflammation, high...

Real-world data show how mirikizumab performs outside clinical trials, especially in patients previously exposed to multiple advanced therapies. That can help patients and clinicians weigh expectations for effectiveness...

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from djournal.com.

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Upadacitinib. The original article is from Przeglad gastroenterologiczny.

Methotrexate is commonly used in IBD, often with biologics, but real‑world data on how long patients stay on it, typical dosing, and safety in large contemporary cohorts are limited.

This study suggests tofacitinib may work quickly as a rescue option for biologic‑naive patients with steroid‑refractory ASUC and that many achieved steroid‑free remission by 24 weeks — information that could matter when...

This is an official prescribing-label update for an adalimumab biosimilar used to treat Crohn’s disease and ulcerative colitis, including pediatric indications and dosing. Changes to indications or pediatric dosing and...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and JAK inhibitor. The original article is from Journal of Crohn's & colitis.

This paper systematically catalogs drugs that have been reported with new or worsening IBD in two large pharmacovigilance databases. Knowing which medications generate strong reporting signals can help clinicians and...

Active IBD was linked to higher risk of RSV infection and more severe respiratory outcomes in this large observational study. That could be relevant for prevention and monitoring during periods of active disease.

Subcutaneous infliximab could offer children with IBD a more convenient dosing route with higher, steadier drug levels while maintaining remission. Insurance and labeling barriers affected access in this US cohort.

For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...

This trial tests whether people with UC in deep remission can safely stop JAK inhibitor therapy — potentially reducing long-term exposure and associated safety concerns while preserving disease control and quality of...

This Phase 2a trial tested a new investigational drug, tulisokibart, in people with moderately to severely active Crohn’s disease who have not done well on prior therapies — so patients and clinicians watching new...

The FDA label for dexamethasone explicitly lists regional enteritis (Crohn's disease) and ulcerative colitis among its gastrointestinal indications, and provides dosing guidance and steroid-equivalent tables that are...

The editorial outlines treatment strategies that could affect whether a person with ASUC avoids colectomy, highlights the importance of getting adequate infliximab exposure, and summarizes emerging drug classes that may...

For people with moderate–severe Crohn’s disease who failed anti‑TNF drugs, this trial suggests risankizumab may achieve higher corticosteroid‑free clinical and endoscopic remission than ustekinumab, which could mean...

A natural compound (diosgenin) reduced disease signs and inflammatory markers in a mouse model of ulcerative colitis, suggesting a possible anti-inflammatory mechanism that could inform future preclinical research.

Many people with IBD who achieve remission ask about reducing or stopping medication. This review summarises current evidence and highlights that withdrawal carries substantial relapse risk and that decisions should be...

A majority of surveyed IBD patients who use marijuana reported better quality of life and relief from symptoms such as nausea, joint pain, insomnia and anxiety — findings of interest to people seeking symptom management...

This trial is testing a new experimental oral therapy (BRS201) aimed at reducing hydrogen sulfide–related metabolites in people with mild ulcerative colitis. If successful, the drug could represent a novel, non-biologic...

This trial tests etrasimod (an S1P receptor modulator) specifically in older adults with active ulcerative colitis — a group often underrepresented in IBD trials. Results could inform safety and short-term remission...

This review pools available pediatric data showing ustekinumab can induce and maintain remission after anti‑TNF failure, offering a treatment option for children with refractory IBD. Results are most robust for Crohn’s...